Are you someone living with locally advanced or metastatic breast cancer?

If so, consider joining the ELAINE-3 study, a clinical trial for people with metastatic ER+/HER2- breast cancer with an ESR1 mutation investigating a  potential new metastatic breast cancer treatment.

Study Overview

Clinical trials help provide patients with new therapies that may work better for them than what is currently available. The ELAINE-3 clinical trial is investigating a targeted endocrine therapy, lasofoxifene, in the treatment of ER+/HER2- metastatic breast cancer. Continue reading to learn more about the study, intervention, and if it may be right for you.

Who is Elaine?

The ELAINE studies are dedicated in memory of Elaine Davidson Nemzer, MD, the sister of Sermonix co-founder Miriam Davidson Portman, MD. Elaine was a brilliant and compassionate child psychiatrist whose life was cut short by metastatic breast cancer at the age of 47. She was the author of several textbook chapters on psychiatry and a dedicated therapist, teacher, colleague, wife, mother, sister, and friend. Even during her illness, she was a source of comfort and hope to all those she encountered, and her spirit continues to serve as an inspiration to the Sermonix team, filling us with passion and purpose.

Learn more about the ELAINE-3 study

Do you qualify?

You may qualify to participate in the ELAINE-3 study if you: